Compare TTEC & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEC | CYPH |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | 69400 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 73.3M |
| IPO Year | 1996 | 2019 |
| Metric | TTEC | CYPH |
|---|---|---|
| Price | $1.48 | $2.93 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 283.9K | ★ 15.9M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.80 | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,509,171,000.00 | $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.71 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $1.18 | $0.49 |
| 52 Week High | $3.99 | $4.19 |
| Indicator | TTEC | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 55.23 |
| Support Level | $1.18 | $0.68 |
| Resistance Level | $2.49 | $3.23 |
| Average True Range (ATR) | 0.05 | 0.48 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 89.66 | 50.35 |
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.